Corient Capital Partners, LLC Alnylam Pharmaceuticals, Inc. Transaction History
Corient Capital Partners, LLC
- $1.34 Billion
- Q3 2022
A detailed history of Corient Capital Partners, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Corient Capital Partners, LLC holds 2,121 shares of ALNY stock, worth $516,527. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,121
Previous 2,121
-0.0%
Holding current value
$516,527
Previous $309,000
-0.0%
% of portfolio
0.02%
Previous 0.02%
Shares
9 transactions
Others Institutions Holding ALNY
# of Institutions
670Shares Held
112MCall Options Held
839KPut Options Held
771K-
Capital World Investors Los Angeles, CA16.6MShares$4.04 Billion0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$3.1 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.33 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA6.97MShares$1.7 Billion0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.38MShares$1.07 Billion0.64% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $30B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...